Lv22
152 积分 2024-10-10 加入
Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents
1小时前
已关闭
Translational Model-Based Strategy to Guide the Choice of Clinical Doses for Antibody-Drug Conjugates
7小时前
已完结
Preclinical Characterization of AMG 424, a Novel Humanized T Cell-Recruiting Bispecific Anti-CD3/CD38 Antibody
17小时前
已完结
Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin
18天前
已完结
Quantitative Pharmacology Methods for Bispecific T Cell Engagers
21天前
已完结
Clinical Pharmacology Characterization of Bispecific T‐Cell Engagers: A Summary Based on FDA Approvals
21天前
已完结
Unlocking the mystery of the PD-1/PD-L1 axis: beyond the checkpoint hype
25天前
已完结
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial
26天前
已完结
Predictive value of serum cytokines in patients with non-small-cell lung cancer receiving anti-PD-1 blockade therapy: a meta-analysis
26天前
已完结
Quantitative Evaluation of the Effect of Antigen Expression Level on Antibody–Drug Conjugate Exposure in Solid Tumor
27天前
已完结
皖公网安备34019202002308
